Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Apr 27;18(1):486.
doi: 10.1186/s12885-018-4406-6.

Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis

Affiliations
Meta-Analysis

Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis

Qiuying Chen et al. BMC Cancer. .

Abstract

Background: Intravenous chemotherapy (IVC) and intra-arterial chemotherapy (IAC) have become the primary treatments for retinoblastoma; however, some controversy remains over which method is more effective. We conducted a meta-analysis to compare the clinical efficacy of IVC and IAC.

Methods: We systematically searched literature published on PubMed, Embase, and Cochrane Library up to May 2017. Studies containing either IAC or IVC that reported on efficacy were included. The effects estimate was expressed as a pooled rate with 95% confidence interval (CI), using a fixed-effects or random-effects model.

Results: Twenty-six studies were identified which included 1541 eyes (IAC: 11 trials, 445 eyes; IVC: 16 trials, 1096 eyes). The mean follow-up times were 49.4 months (range, 13.0-105.3 months) for IVC and 21.7 months (range, 8.8-38.7 months) for IAC. For the International Classification of Intraocular Retinoblastoma (ICRB) grading, the overall success rate was higher with IAC than with IVC (75.7% [95%CI: 65.7%-83.6%] vs. 69.5% [95%CI: 51.9%-82.8%], P < 0.001). The globe salvage with IAC was higher than with IVC in group D eyes (79.5% [95%CI: 71.8%-85.4%] vs. 55.1% [95%CI: 45.6%-64.2%], P < 0.001), but not in groups B (95.8% [95%CI: 57.5%-99.7%] vs. 82.5% [95%CI: 58.9%-94.0%], P = 0.163), C (91.3% [95%CI: 65.9%-98.3%] vs. 89.0% [95%CI: 69.0%-96.7%], P = 0.212), and E eyes (51.2% [95%CI: 37.0%-65.2%] vs. 43.2% [95%CI: 18.3%-72.1%], P = 0.578). IAC and IVC were not significantly different regarding the recurrence and metastasis rates (15.0% vs. 15.4%, P = 0.148 and 2.7% vs. 0.6%, P = 0.194, respectively). For Reese-Ellsworth (RE) grading, IAC had a higher globe salvage in groups IV (90.9% [95%CI: 56.0%-98.7%] vs. 66.3% [95%CI: 32.4%-89.0%], P = 0.047) and V eyes (83.2% [95%CI: 72.0%-90.5%] vs. 59.9% [95%CI: 43.1%-74.6%], P = 0.003), but not in group I-III eyes (88.6% [95%CI: 58.3%-97.7%] vs. 88.1% [95%CI: 76.6%-94.4%], P = 0.244). The overall success rate was higher in IAC than in IVC (87.1% [95%CI: 78.1%-92.7%] vs. 77.3% [95%CI: 68.1%-84.4%], P = 0.033).

Conclusions: IAC may be superior to IVC for the treatment of retinoblastoma, with a higher overall success rate and higher globe salvage in group D or groups IV and V eyes.

Keywords: Intra-arterial chemotherapy; Intravenous chemotherapy; Meta-analysis; Retinoblastoma.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This meta-analysis was approved by the institutional review board, the need for informed patient consent for inclusion was waived.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
The technique of intra-arterial chemotherapy (IAC) treatment. a: An arteriogram was performed to indicate the takeoff of the ophthalmic artery from the internal carotid artery. b: Using fluoroscopy and roadmap guidance, the microcatheter selectively catheterized the ophthalmic artery. c: As soon as the microcatheter was in a stable position at the ostium of the ophthalmic artery, then pulse-inject drugs
Fig. 2
Fig. 2
The fundus photographs of group A-E eyes of retinoblastoma. Group A: Eyes with small discrete tumors away from critical structures; Group B: Eyes with no vitreous or subretinal seeding and discrete retinal tumor of any size or location; Group C: Eyes with only focal vitreous or subretinal seeding and discrete retinal tumors of any size and location; Group D: Eyes with diffuse vitreous or subretinal seeding and/or massive, nondiscrete endophytic or exophytic disease; Group E: Eyes that have been destroyed anatomically or functionally by the tumor
Fig. 3
Fig. 3
The literature screening flowchart

References

    1. Narang S, Mashayekhi A, Rudich D, Shields CL. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clin Exp Ophthalmol. 2012;40:736–742. doi: 10.1111/j.1442-9071.2012.02757.x. - DOI - PubMed
    1. Rothschild PR, Levy D, Savignoni A, Lumbroso-Le Rouic L, Aerts I, Gauthier-Villars M, Esteve M, Bours D, Desjardins L, Doz F, Levy-Gabriel C: Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study. Eye (Lond) 2011, 25:1555–1561. - PMC - PubMed
    1. Canturk S, Qaddoumi I, Khetan V, Ma Z, Furmanchuk A, Antoneli CB, Sultan I, Kebudi R, Sharma T, Rodriguez-Galindo C, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol. 2010;94:1432–1436. doi: 10.1136/bjo.2009.168062. - DOI - PubMed
    1. MacCarthy A, Birch JM, Draper GJ, Hungerford JL, Kingston JE, Kroll ME, Stiller CA, Vincent TJ, Murphy MF. Retinoblastoma: treatment and survival in great Britain 1963 to 2002. Br J Ophthalmol. 2009;93:38–39. doi: 10.1136/bjo.2008.139626. - DOI - PubMed
    1. Kupfer C. Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol. 1953;36:1721–1723. doi: 10.1016/0002-9394(53)90009-9. - DOI - PubMed

Publication types

MeSH terms